Incidence of breast cancer in a cohort of 5,135 transgender veterans

  title={Incidence of breast cancer in a cohort of 5,135 transgender veterans},
  author={George R. Brown and Kenneth T. Jones},
  journal={Breast Cancer Research and Treatment},
Abstract Transgender (TG) persons often receive, or self-treat, with cross-sex hormone (CSH) treatments as part of their treatment plans, with little known about their incidence of breast cancer. This information gap can lead to disparities in the provision of transgender health care. The purpose of the study was to examine the incidence of breast cancer in the largest North American sample of TG patients studied to date to determine their exposure to CSH, incidence of breast cancer, and to… 

Breast Cancer Risk and Screening in Transgender Individuals

The risk of breast cancer development in transgender individuals is different compared to that of the cis-gender population, and further prospective data are needed to appropriately quantify these risks and to assess what is the appropriate breast cancer screening recommendations for this population.

Breast cancer and its impact in male transsexuals

Understanding the need for mammography in these often marginalized groups is very important in addressing breast cancer disparities despite differences in insurance coverage in some countries and greater concern for the cancer of the breast in residual breast tissue.

Breast Cancer in Transgender Veterans: A Ten-Case Series.

  • G. Brown
  • Medicine, Psychology
    LGBT health
  • 2015
The cases of breast cancer in patients with a diagnosis consistent with transgender identification in the Veterans Health Administration (1996-2013) support the importance of screening for breast cancer using standard guidelines in birth sex males and females.

Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern, suggesting that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.

Breast Cancer Screening, Management, and a Review of Case Study Literature in Transgender Populations

Existing evidence on breast cancer incidence in transgender women and men is described, and rational recommendations regarding the screening for and approach to managing breast cancer in transgender populations are made.

Evaluating Risks, Reported Cases and Screening Recommendations for Breast Cancer in Transgender Patients

The existing literature is examined, the current data on the potential risks associated with HRT are outlined, and a 3-pronged approach to communicate risk, screen, and diagnose breast cancer in transgender patient populations is provided.

Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults.

A retrospective literature review of studies from the last 15 years on breast cancer rates and identified risks in TG persons suggests higher than previously believed rates of breast cancer in TG women compared with cisgender men and risk correlating with duration of hormone use.

Breast Imaging in Transgender Patients

It is proposed that transgender women follow the screening guidelines for natal females if they have risk factors for breast cancer and received hormone therapy for > 5 years, but further research is necessary, especially in transgender women who have no risk factors or received hormones therapy for ≤ 5 years.

Cancer Screening for Transgender and Gender Diverse Patients

The incidence of sex steroid–influenced cancers among TGD persons appears to be low, but gender-affirming therapies may influence cancer risk, and the patient experience and potential barriers in access should be considered in the development of TGD-specific screening guidelines.



Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals.

Alcohol Drinking May Increase Risk of Breast Cancer in Men: A European Population-Based Case–Control Study

It is found that the relative risk of breast cancer in men is comparable to that in women for alcohol intakes below 60 g per day, and continues to increase at high consumption levels not usually studied in women.

Examining Patient Conceptions: A Case of Metastatic Breast Cancer in an African American Male to Female Transgender Patient

Analysis suggests dissociation between the patient’s social and biological identities, fear and fatalism around cancer screening, and legitimization of injectable hormones in this case.

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

The sharp decrease in incidence from 2002 to 2003 that occurred in women 50 to 69 years old who predominantly, but not exclusively, had ER+ tumors may reflect the early benefit of the reduced use of hormone replacement therapy.

Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking.

Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy

All hormonal pathways included in this complex hormonal and surgical procedure of transgender surgery have important implications for women undergoing prophylactic mastectomy because of a high risk of possible breast cancer.

A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.

The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe.

Risk of breast cancer in male BRCA2 carriers

The risk of breast cancer for unaffected men who test positive for a BRCA2 mutation is based on very few retrospective studies but this analysis confirmed that breast cancer risk in men was 7.1% ( SE 5.2–8.6%) by age 70 years and 8.4% (SE 6.2-10.6) by age 80  years.

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management.